Chiglitazar Sodium Combined With Venetoclax and Azacitidine (CVA) for the Treatment of R/R AML

Clinical trial NCT06737523 · RECRUITING

Trial details

NCT number: NCT06737523
Sponsor: The First Affiliated Hospital of Xiamen University
Status: RECRUITING
Phase: Phase 1
Study type: INTERVENTIONAL

Acute Myeloid Leukemia Relapse Refractory AML

Start date: 2025-03-15
Primary completion: 2025-12-31
Enrollment: 30

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.